论文部分内容阅读
目的探讨乳腺癌患者术前采用吡柔比星、环磷酰胺联合多西他赛(TAC)方案治疗的临床疗效。方法选取2012年4月至2013年3月间收治的IIA~IIIC期乳腺癌患者94例,按照随机数字表法分为TAC方案治疗的观察组(47例)和吡柔比星、环磷酰胺联合氟尿嘧啶(CAF)方案治疗的对照组(47例),分析两组患者的近期疗效和不良反应。结果两组患者的总有效率、病理完全缓解率和降期率差异有统计学意义(P<0.05)。观察组患者和对照组患者的淋巴结阴转率分别为38.1%和24.3%(P<0.05)。两组患者的III~IV级白细胞减少发生率差异有统计学意义(P<0.05);I~II级血小板、血红蛋白和白细胞减少等血液学不良反应,经及腹泻、脱发、恶心呕吐、心脏毒性和神经毒性等比较,差异无统计学意义(P>0.05)。结论 TAC方案可作为乳腺癌手术患者的新辅助化疗方案,患者耐受性好,疗效明显。
Objective To investigate the clinical effect of preoperative use of pirarubicin and cyclophosphamide in combination with docetaxel (TAC) in patients with breast cancer. Methods Ninety-four patients with stage IIA-IIIC breast cancer who were admitted from April 2012 to March 2013 were divided into observation group (n = 47) and pirarubicin group treated with TAC regimen according to random number table, cyclophosphamide In the control group (47 cases) treated with the combination of fluorouracil (CAF) regimen, the short-term efficacy and adverse reactions of the two groups were analyzed. Results The total effective rate, complete pathological response rate and the rate of decline in the two groups were significantly different (P <0.05). The negative conversion rates of lymph nodes in observation group and control group were 38.1% and 24.3%, respectively (P <0.05). There were significant differences in the incidence of grade III-IV leukopenia between the two groups (P <0.05). Hematologic adverse reactions such as platelet, hemoglobin and leucocytopenia of grade I to II were significantly different from those of the controls in diarrhea, hair loss, nausea and vomiting, cardiotoxicity Compared with neurotoxicity, the difference was not statistically significant (P> 0.05). Conclusion The TAC regimen can be used as a neoadjuvant chemotherapy regimen for breast cancer patients. The patients are well tolerated and have a good curative effect.